About: Cheolwon Suh

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cheolwon Suh Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher (ORCID 0000-0002-9178-4431)

Attributes	Values
rdf:type	Item
description	araştırmacı (tr) wetenschapper (nl) дослідник (uk) médicu surcoreanu (ast) researcher (ORCID 0000-0002-9178-4431) (en) 서울아산병원 의사 (ko)
rdfs:label	Cheolwon Suh (en) Cheolwon Suh (nl) Cheolwon Suh (ast) 서철원 (ko)
skos:prefLabel	Cheolwon Suh (en) Cheolwon Suh (nl) Cheolwon Suh (ast) 서철원 (ko)
name	Cheolwon Suh (en) Cheolwon Suh (nl) Cheolwon Suh (ast) 서철원 (ko)
given name	wds:Q92139867-ee90f424-427d-2a3b-e670-98e0cc050476
given name	Cheol-won
instance of	wds:Q92139867-726F6F4D-3F5D-4E77-BCE7-F19EC36D15AD
instance of	Homo sapiens
occupation	wds:Q92139867-2FF12F65-E905-445C-9239-3B66290FE471
employer	wds:Q92139867-83a7ec8e-4f75-f8b2-42b6-1ae18da55543
sex or gender	wds:Q92139867-9ebc2482-42b7-9af7-3256-5f65d12b085e
country of citizenship	wds:Q92139867-cbb99656-4fdc-f9a7-d7cb-f9dc23c027e3
family name	wds:Q92139867-f9782bd7-45f7-0f9b-1234-b9dbdfc34d62
occupation	physician
employer	Asan Medical Center
sex or gender	male
country of citizenship	Korea
family name	Seo
ORCID iD	wds:Q92139867-A46F0972-60E4-4B8E-B319-2B5C7E36BA40
ORCID iD	https://orcid.org/0000-0002-9178-4431
ORCID iD	0000-0002-9178-4431
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q92139867
is author of	Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study Leptomeningeal carcinomatosis in gastric cancer. CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas Clinical features and prognostic model for extranasal NK/T-cell lymphoma. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm. Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement Prognostic factors in non-Hodgkin's lymphoma patients treated by autologous stem cell transplantation: a single center experience Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas Myelomatous pleural effusion: a case series in a single institution and literature review Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly dia Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages. The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial High concordance of gene expression profiling-correlated immunohistochemistry algorithms in diffuse large B-cell lymphoma, not otherwise specified. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of lymphomas Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000 The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software